Cagla Kayabasi
Overview
Explore the profile of Cagla Kayabasi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
147
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ozel B, Kipcak S, Caglar H, Kayabasi C, Bagca B, Gunduz C, et al.
Cell Biochem Biophys
. 2024 Dec;
PMID: 39690396
Lung cancer (LC) accounts for approximately 25% of all cancer cases, with 80-85% of these being non-small cell lung cancer (NSCLC). VS-5584 is a novel anti-cancer agent that specifically inhibits...
2.
Kamer S, Yilmaz Susluer S, Balci Okcanoglu T, Kayabasi C, Ozmen Yelken B, Hoca S, et al.
Cancer Med
. 2023 Sep;
12(19):19874-19888.
PMID: 37754559
Background: The optimal radiobiological model, which assesses the biological effects of novel radiotherapy techniques that concurrently modify multiple physical factors, has not yet been defined. This study aimed to investigate...
3.
Kayabasi C, Gunduz C
Nucleosides Nucleotides Nucleic Acids
. 2023 Jul;
43(2):99-115.
PMID: 37470414
Genetic and/or epigenetic alterations in hematopoietic stem cells (HSCs) contribute to leukemia stem cell (LSC) formation. We aimed to identify alterations in the lncRNA expression profile signature of LSCs upon...
4.
Gasimli R, Kayabasi C, Ozmen Yelken B, Asik A, Sogutlu F, Celebi C, et al.
Int J Radiat Biol
. 2023 Jun;
99(12):1961-1970.
PMID: 37389464
Purpose: PI3K/Akt/mTOR pathway activation causes relapse and resistance after radiotherapy in breast cancer (BC). We aimed to radiosensitize BC cell lines to irradiation (IR) by PKI-402, a dual PI3K/mTOR inhibitor....
5.
Kayabasi C, Yilmaz Susluer S, Balci Okcanoglu T, Ozmen Yelken B, Mutlu Z, Bagca B, et al.
Nutr Cancer
. 2022 May;
74(10):3679-3691.
PMID: 35608652
is used in folk medicine due to its anti-inflammatory, antimicrobial, and antioxidant properties. Ponatinib, an effective tyrosine kinase inhibitor in the treatment of chronic myeloid leukemia (CML), has severe side...
6.
Kayabasi C, Caner A, Yilmaz Susluer S, Balci Okcanoglu T, Ozmen Yelken B, Asik A, et al.
Med Oncol
. 2022 Jan;
39(3):29.
PMID: 35059859
LncRNAs are associated with malignancies with their tumor suppressor/oncogenic properties. Although many studies are conducted related to the mechanism of action for dasatinib and ponatinib in chronic myeloid leukemia (CML),...
7.
Kayabasi C, Ozmen Yelken B, Asik A, Balci Okcanoglu T, Sogutlu F, Gasimli R, et al.
Eur J Pharmacol
. 2021 Aug;
910:174446.
PMID: 34461124
Ponatinib is used for advanced treatment of chronic myeloid leukemia (CML), although low doses to prevent side effects do not suppress survival pathways and eradicate leukemia stem cells (LSCs). We...
8.
Balc-Okcanoglu T, Yilma-Susluer S, Kayabasi C, Ozme-Yelken B, Biray-Avci C, Gunduz C
Mol Biol Res Commun
. 2021 Mar;
10(1):39-43.
PMID: 33681396
We aimed to find the effect of caffeic acid phenethyl ester (CAPE) on the expression profiles of cell cycle control genes in breast cancer cell line (MCF-7). The cytotoxic effect...
9.
Akgul O, Erdogan M, Birim D, Kayabasi C, Gunduz C, Armagan G
Turk J Chem
. 2021 Jan;
44(6):1674-1693.
PMID: 33488262
In this study, a group of 4-substituted benzoyltaurinamide derivatives were designed, synthesized, and investigated for their anticancer activity against three cancer cell lines and one nontumorigenic cell line by MTT...
10.
Sogutlu F, Kayabasi C, Yelken B, Asik A, Gasimli R, Kipcak S, et al.
Anticancer Agents Med Chem
. 2020 Oct;
21(12):1564-1574.
PMID: 33106151
Background: Dysregulation of the cell cycle is one of the main causes of melanomagenesis. Genomewide studies showed that the expression of Aurora -A and -B significantly has been upregulated in...